Vernalis and Servier signed a three-year collaboration to harness Vernalis’ fragment- and structure-based drug discovery platform for the identification of drug candidates against a new cancer target.

The deal is in addition to the companies’ existing collaboration, signed in May 2007, focused on two oncology targets involved in protein-protein interactions. In October 2008, Vernalis received a €500,000 milestone from Servier for solving the novel crystal structure of one of the targets.

This site uses Akismet to reduce spam. Learn how your comment data is processed.